Ocrevus
Active substance: ocrelizumab
ocrelizumab
Centralised EU authorisationActive
Marketing holder: Roche Registration GmbH
Verified 2026-10-09 · EMA
Analogues in other countries- Source: EMA
- Countries with the substance registered: 3
Composition
Analogues by country
Products with the same active substance registered in other countries.
| Country | Products |
|---|---|
| RU 3 |
|
| US 2 |
|
Import and control
Control by country
- Russiaprescription only
Source: GRLS (Russian state register) · record 01a120c3-2fe9-7ae6-85e4-405dc5672986,01a120c3-54c3-7a50-8af2-77bb45290e15,01a120c3-f8c5-7032-920a-c4d592f8b263;count=3 · valid from 2026-10-09 · verified 2026-10-09
- United Statesprescription only
Source: openFDA NDC · record 01a12093-93bf-762b-9927-493f2dcd6314;count=1 · valid from 2026-10-09 · verified 2026-10-09
Registration
- Registration number
- EMEA/H/C/004043
- Registration status
- Active
- ATC code
- L04AG08
Sources
- product · EMA · EMEA/H/C/004043 · Verified 2026-10-09
- registration_status · EMA · EMEA/H/C/004043 · Verified 2026-10-09
- ingredients.0 · EMA · EMEA/H/C/004043 · Verified 2026-10-09